Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, developing precision therapies for solid tumors that aim to preserve organ function. News about AURA stock frequently centers on clinical trial milestones, regulatory designations, financing activities, and participation in healthcare and investor conferences.
A key theme in Aura’s news flow is progress with its lead candidate, bel-sar (AU-011). The company regularly reports updates on the global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, which it describes as the first registration-enabling study in this indication. Press releases also cover developments in additional ocular oncology programs, including metastases to the choroid and cancers of the ocular surface, and in non-muscle invasive bladder cancer, where Aura has shared Phase 1 data and details of an ongoing Phase 1b/2 trial.
Investors following AURA news can expect recurring coverage of regulatory interactions, such as Orphan Drug and Fast Track designations for bel-sar, as well as financial updates through quarterly and annual results furnished via Form 8-K. Aura’s announcements also include public offering details, cash runway commentary, and information about patent applications for new formulations of bel-sar in urologic oncology.
In addition, Aura frequently announces participation in healthcare and life sciences conferences, fireside chats, and investor events, where senior management discusses the company’s pipeline and strategy. For anyone tracking AURA, this news page provides a centralized view of Aura Biosciences’ clinical progress, corporate developments, and capital markets activity over time.
Aura Biosciences (NASDAQ: AURA) announced FDA Fast Track Designation for belzupacap sarotalocan (bel-sar) to treat choroidal metastasis, signifying a significant opportunity for a new standard of care. Following positive Phase 2 results for early-stage choroidal melanoma, the global Phase 3 trial is set to begin dosing in 1H 2023. Financial results reveal a cash position of $188.8 million, sufficient to fund operations into 2025.
However, R&D expenses surged to $42.2 million, contributing to a net loss of $58.8 million for the year.
Aura Biosciences, Inc. (Nasdaq: AURA) announced positive interim Phase 2 safety and efficacy data for its treatment, bel-sar, aimed at early-stage choroidal melanoma. Results showed an impressive 100% tumor control rate and an 88% visual acuity preservation rate after an average of nine months follow-up in patients. The therapy demonstrated favorable safety, with only one case of visual acuity loss and no serious adverse events reported. Aura plans to initiate a global Phase 3 trial this year, bolstering confidence in bel-sar's potential as a first-line treatment. These results were presented at the Macula Society’s 46th Annual Meeting in Miami, FL.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotech firm, focuses on developing virus-like drug conjugate (VDC) therapies for oncology. CEO Elisabet de los Pinos will present at the SVB Securities Global Biopharma Conference on February 16, 2023 at 12:00 p.m. ET and at the 43rd Annual Cowen Healthcare Conference on March 8, 2023, participating in an auditory and ophthalmology panel at 12:50 p.m. ET. These events will be accessible via live webcasts on Aura's website, where replays will be available for 90 days.
Aura's lead VDC candidate, bel-sar, targets ocular cancers and is in a Phase 3 trial for treating early-stage choroidal melanoma.
Aura Biosciences, Inc. has announced the pricing for an underwritten public offering of 6,700,000 shares of its common stock at $12.00 per share, aiming to raise gross proceeds of approximately $80.4 million. The offering is expected to close by December 5, 2022, pending customary closing conditions. Aura has also offered underwriters a 30-day option to purchase up to 1,005,000 additional shares. This capital is intended to support the development of its virus-like drug conjugate therapies targeting multiple oncology indications, particularly for ocular cancers.
Aura Biosciences, Inc. (NASDAQ: AURA) announced an underwritten public offering of its common stock, with all shares being offered by the company. The offering is subject to market conditions, and underwriters may purchase an additional 15% of shares. The offering follows a shelf registration statement filed with the SEC. Aura is focused on developing virus-like drug conjugate therapies for various oncology indications, including a global Phase 3 trial for treating choroidal melanoma.
Aura Biosciences reported its Q3 2022 financial results, highlighting significant clinical advancements in its oncology programs. The company announced the global Phase 3 trial design for belzupacap sarotalocan in treating early-stage choroidal melanoma, marking a milestone in vision-preserving therapy. A first patient has been dosed in a Phase 1 study for non-muscle invasive bladder cancer. Financially, Aura’s cash position is $111.5 million, expected to fund operations until 2024. However, R&D and G&A expenses have increased, leading to a net loss of $15.9 million for Q3 2022.
Aura Biosciences Inc. (NASDAQ: AURA) has announced the initiation of startup activities for a global Phase 3 trial for its drug belzupacap sarotalocan (bel-sar), aimed at treating early-stage choroidal melanoma. This follows positive interim data from a Phase 2 trial presented at the American Academy of Ophthalmology. The trial will evaluate bel-sar's safety and efficacy compared to a sham treatment. Approximately 75 patients will be enrolled, with a focus on those with documented tumor growth to enhance trial efficiency.
Aura Biosciences (NASDAQ: AURA), a clinical-stage biotechnology company, announced participation in key investor conferences. The executive team will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 10:55 a.m. ET, and hold a fireside chat at the 5th Annual 2022 Evercore ISI HealthCONx on November 29, 2022, at 8:25 a.m. ET. Webcasts of both events will be accessible on the company’s website for 90 days post-event. Aura specializes in virus-like drug conjugates for various oncology treatments, including ocular cancers.
Aura Biosciences (NASDAQ: AURA) announced encouraging interim Phase 2 data for its first virus-like drug conjugate, belzupacap sarotalocan (AU-011), targeting early-stage choroidal melanoma. The data, presented at the American Academy of Ophthalmology 2022 Annual Meeting, showed a significant reduction in tumor growth rates (-0.296 mm/yr, p = 0.0007) and an 88.9% tumor control rate after three cycles of treatment. The therapy demonstrated favorable safety and a potential for vision preservation in patients lacking treatment options. A virtual Investor Day was scheduled to discuss these findings further.
Aura Biosciences Inc. (NASDAQ: AURA) has announced the dosing of the first patient in a Phase 1 clinical trial of belzupacap sarotalocan, aimed at treating Non-Muscle Invasive Bladder Cancer (NMIBC). This trial marks a significant milestone in urologic oncology, addressing a high unmet medical need. The trial will enroll 23 patients to evaluate the safety and tolerability of the treatment. Previously, the FDA granted Fast Track designation for this candidate, facilitating more frequent consultations regarding its clinical development.